Search Result

Results for "

5-deaza-5,6,7,8-tetrahydrofolic acid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylin Receptor (1) Amyloid-β (1) Antibiotic (1) Antifolate (6) Bacterial (4) Biochemical Assay Reagents (11) Calcium Channel (2) CGRP Receptor (2) Chemerin Receptor (1) DNA/RNA Synthesis (12) Drug Derivative (4) Drug Metabolite (2) Endogenous Metabolite (7) Ephrin Receptor (1) Fungal (1) GCGR (9) GLP Receptor (11) HIV (1) HSV (1) Isotope-Labeled Compounds (6) MARCKS (2) Melanocortin Receptor (1) Natriuretic Peptide Receptor (NPR) (1) Neuropeptide Y Receptor (1) Nucleoside Antimetabolite/Analog (20) Opioid Receptor (1) PD-1/PD-L1 (2) Phosphatase (1) Phospholipase (1) Phosphoramidites (3) PKC (2) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Renin (1) RXFP Receptor (1) Telomerase (1) Vasopressin Receptor (3)
By Research Areas:	Cancer (19) Cardiovascular Disease (2) Endocrinology (1) Infection (8) Inflammation/Immunology (8) Metabolic Disease (30) Neurological Disease (8)
Click Chemistry:	Azide (1)
Oligonucleotides:	Adenosine (5) Guanosine (5) Nucleotide Analogs (7) Nucleoside Analogs (17) Uridine (4) Adenine (1) Phosphoramidites (3) Guanine (2) Adenine Nucleotide (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-14520

Tetrahydrofolic acid 5+ Cited Publications L-5,6,7,8-tetrahydrofolic acid; L-tetrahydrofolic acid	Endogenous Metabolite	Metabolic Disease
Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid .

HY-P3462

Cagrilintide 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-112169A

10-Formyltetrahydrofolic acid disodium	Endogenous Metabolite	Metabolic Disease
10-Formyltetrahydrofolic acid disodium is a form of tetrahydrofolic acid that acts as a donor of formyl groups in anabolism. 10-Formyltetrahydrofolic acid disodium can be used as a substrate for formyltransferase reactions and is involved in the biosynthesis of purines .

HY-14518

Aminopterin 4-Aminofolic acid; APGA	Antifolate	Inflammation/Immunology Cancer
Aminopterin (4-Aminofolic acid), the 4-amino derivative of folic acid, is a folic acid antagonist. Aminopterin catalyses the reduction of folic acid to tetrahydrofolic acid, and competitively inhibits dihydrofolate reductase (DHFR) with a K_i of 3.7 pM. Aminopterin has anticancer and immunosuppressive activity. Aminopterin is used in treatment of pediatric leukemia .

HY-112169

10-Formyltetrahydrofolic acid	Endogenous Metabolite	Metabolic Disease
10-Formyltetrahydrofolic acid is a form of tetrahydrofolic acid that acts as a donor of formyl groups in anabolism. 10-Formyltetrahydrofolic acid can be used as a substrate for formyltransferase reactions and is involved in the biosynthesis of purines .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-14520S

Tetrahydrofolic acid-d4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Tetrahydrofolic acid-d₄ is the deuterium labeled Tetrahydrofolic acid. Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid .

HY-P10218

MANS peptide 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10271

RG7697 NNC0090-2746; MAR709; RO6811135	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-W048490

*7-Deaza-2'-deoxy-7-iodoadenosine*	DNA/RNA Synthesis	Others
7-Deaza-2'-deoxy-7-iodoadenosine is an important deoxynucleoside that can be used in the synthesis of other active compounds .

HY-P10218A

MANS peptide TFA 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P11273

Urcosimod OK 101	Chemerin Receptor	Neurological Disease Inflammation/Immunology
Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .

HY-P11290

MC4-NN2-0453	Melanocortin Receptor	Metabolic Disease
MC4-NN2-0453, a α-MSH analog, is a selective MC4R agonist. MC4-NN2-0453 can be used for obesity research .

HY-14520S1

Tetrahydrofolic acid-13C5 L-5,6,7,8-tetrahydrofolic acid-¹³C₅; L-tetrahydrofolic acid-¹³C₅	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Tetrahydrofolic acid- ¹³C₅ (L-5,6,7,8-Tetrahydrofolic acid- ¹³C₅) is ¹³C labeled Tetrahydrofolic acid. Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid .

HY-W048513

*7-Deaza-2'-deoxyadenosine*	DNA/RNA Synthesis	Cancer
7-Deaza-2'-deoxyadenosine is an isosteric dATP analog of 2'-deoxyadenosine. 7-Deaza-2'-deoxyadenosine is recognized by various DNA polymerases and incorporated into DNA strands as a substrate. 7-Deaza-2'-deoxyadenosine undergoes a bioorthogonal inverse electron demand Diels-Alder reaction with tetrazine-modified molecules, enabling site-specific labeling of DNA, surface antibody immobilization and intracellular fluorescent labeling. 7-Deaza-2'-deoxyadenosine reduces the DNA curvature of d(A₆)·d(T₆) fragments and the stability of DNA/RNA double helices, and leads to decreased antisense activity against SV40 T Antigen. 7-Deaza-2'-deoxyadenosine finds application in the research field of SV40 T Antigen-related cancers .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-W048492

*7-Iodo-7-deaza-2'-deoxyguanosine* 7-deaza-7-Iodo-2'-deoxyguanosine	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Others
7-Iodo-7-deaza-2'-deoxyguanosine (7-Deaza-7-Iodo-2'-deoxyguanosine) is a modified deoxyguanosine nucleoside. 7-Iodo-7-deaza-2'-deoxyguanosine is used in DNA synthesis and sequencing reactions .

HY-138590

*7-TFA-ap-7-Deaza-dA*	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Cancer
7-TFA-ap-7-Deaza-dA is a modified nucleoside. 7-TFA-ap-7-Deaza-dA can be used in the synthesis of deoxyribonucleic acid or nucleic acid. 7-TFA-ap-7-Deaza-dA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-169089

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-W091788

*(2S,3R,5S)-7-Deaza-2'-deoxy-7-iodoadenosine*	Nucleoside Antimetabolite/Analog	Others
(2S,3R,5S)-7-Deaza-2'-deoxy-7-iodoadenosine is the isomer of 7-Deaza-2'-deoxy-7-iodoadenosine (HY-W048490), and can be used as an experimental control. 7-Deaza-2'-deoxy-7-iodoadenosine is a modified oligonucleotide containing 7-Deazaadenine .

HY-134269A

8-Br-7-CH-cADPR disodium 7-deaza-8-bromo-cADPR disodium; 7-deaza-8-bromo-cyclic ADP ribose disodium	Calcium Channel	Neurological Disease
8-Br-7-CH-cADPR disodium (7-Deaza-8-bromo-cADPR) is a potent cADPR antagonist. 8-Br-7-CH-cADPR disodium shows partial inhibition of calcium elevation caused by sTIR dimerization. 8-Br-7-CH-cADPR disodium significantly decreases Paclitaxel (HY-B0015)-induced axon degeneration .

HY-152815

*2′-Deoxy-2′-fluoro-3-deaza-arabinouridine*	Nucleoside Antimetabolite/Analog	Others
2′-Deoxy-2′-fluoro-3-deaza-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-132384S

5-Methyltetrahydrofolic acid-d3 5-Methyl THF-d₃; 5-MTHF-d₃	Isotope-Labeled Compounds	Others
5-(Methyl-d₃)tetrahydrofolic Acid is the deuterium labeled 5-(Methyl)tetrahydrofolic Acid .

HY-14520B

Tetrahydrofolic acid trihydrochloride L-5,6,7,8-tetrahydrofolic acid trihydrochloride; L-tetrahydrofolic acid trihydrochloride	Endogenous Metabolite	Metabolic Disease
Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) trihydrochloride is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid trihydrochloride is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid trihydrochloride serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid .

HY-P11233

Acmopatide	GLP Receptor	Metabolic Disease
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-14520A

*(6S)-Tetrahydrofolic* acid** (6S)-5,6,7,8-tetrahydrofolic acid	Endogenous Metabolite	Metabolic Disease
(6S)-Tetrahydrofolic acid is 1000-fold more active than the (6R) form at promoting the binding of fluorodeoxyuridylate to thymidylate synthase and 600-fold more active as a growth factor of P. cerevisiae. (6S)-Tetrahydrofolic acid also has a low affinity and high dissociation rate for folate-binding protein .

HY-W250161

*7-Deaza-2′-deoxyguanosine 5′-triphosphate* 7-deaza-2'-dGTP	Telomerase	Cancer
7-Deaza-2′-deoxyguanosine 5′-triphosphate (7-Deaza-2'-dGTP), a nucleotide analogue, is a telomerase inhibitor (IC₅₀: 11 μM) .

HY-126877

*3-Deaza-2'-deoxyadenosine*	HSV	Infection
3-Deaza-2 '-deoxyadenosine is a nucleoside analog synthesized from 2' -deoxyadenosine. 3-Deaza-2 '-deoxyadenosine inhibits RNA synthesis by binding to ribose fragments of ribonucleotides, thereby preventing the formation of enzyme-substrate complexes, thereby preventing chain elongation, It can also inhibit DNA synthesis by binding deoxyribose fragments of DNA and preventing DNA polymerase from adding nucleotides to the growth chain. 3-Deaza-2 '-deoxyadenosine has antiviral activity .

HY-W048479

*7-Iodo-2',3'-dideoxy-7-deaza-guanosine* 1 Publications Verification	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis	Others
7-Iodo-2',3'-dideoxy-7-deaza-guanosine is a dideoxynucleoside that can be used in DNA synthesis and sequencing reactions .

HY-P0041A

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-169089A

RP-182-PEG3-K(palmitic acid)-NH2 TFA	Drug Derivative	Cancer
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P1614

ZEP-3	Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
ZEP-3 is a tetrapeptide derivative with anti-aging activity for the skin. ZEP-3 can inhibit ROS production and alleviate oxidative stress .

HY-139743

Aditoprime Aditoprim	Antifolate Bacterial	Infection
Aditoprime (Aditoprim) is a selective bacterial dihydrofolate reductase (DHFR) inhibitor with IC₅₀s of 47 and 520 nM for E.coli and L.casei DHFR, respectively. Aditoprime inhibits the transformation of dihydrofolic acid to tetrahydrofolic acid. Aditoprime has a broad-spectrum antibacterial activity and excellent pharmacokinetics .

HY-P0014A

Liraglutide acetate	GLP Receptor	Metabolic Disease
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-113560

Plipastatin B1	Antibiotic Fungal Phospholipase	Infection
Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A₂ (PLA2), which has antifungal activity .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

HY-P11243

EphA4 agonist compound 23	Ephrin Receptor	Neurological Disease
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .

HY-138592

*7-Deaza-2',3'-dideoxyguanosine* 7-deaza-ddG	HIV	Infection
7-Deaza-2',3'-dideoxyguanosine (7-Deaza-ddG) is a 2′,3′-dideoxynucleoside 5′-triphosphate, which can inhibit HIV-1 reverse transcriptase with a K_i of 25 nM .

HY-132144A

*7-Deaza-7-propargylamino-dGTP sodium*	Biochemical Assay Reagents	Others
7-Deaza-7-propargylamino-dGTP sodium is the sodium salt form of 7-Deaza-7-propargylamino-dGTP (HY-132144). 7-Deaza-7-propargylamino-dGTP sodium is an analog of deoxyguanosine triphosphate dGTP (HY-W008661) and can be used for gene sequencing .

Cat. No.	Product Name	Target	Research Area

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P3462

Cagrilintide 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10218

MANS peptide 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10271

RG7697 NNC0090-2746; MAR709; RO6811135	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P10218A

MANS peptide TFA 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P11273

Urcosimod OK 101	Chemerin Receptor	Neurological Disease Inflammation/Immunology
Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .

HY-P11290

MC4-NN2-0453	Melanocortin Receptor	Metabolic Disease
MC4-NN2-0453, a α-MSH analog, is a selective MC4R agonist. MC4-NN2-0453 can be used for obesity research .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-169089

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P11233

Acmopatide	GLP Receptor	Metabolic Disease
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P0041A

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-169089A

RP-182-PEG3-K(palmitic acid)-NH2 TFA	Drug Derivative	Cancer
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P1614

ZEP-3	Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
ZEP-3 is a tetrapeptide derivative with anti-aging activity for the skin. ZEP-3 can inhibit ROS production and alleviate oxidative stress .

HY-P0014A

Liraglutide acetate	GLP Receptor	Metabolic Disease
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-113560

Plipastatin B1	Antibiotic Fungal Phospholipase	Infection
Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A₂ (PLA2), which has antifungal activity .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

HY-P11243

EphA4 agonist compound 23	Ephrin Receptor	Neurological Disease
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P0041

F992	Vasopressin Receptor	Neurological Disease
F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P4837

Ac-Lys-D-Ala-D-lactic acid	Peptides	Others
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10869

dCNP 1 Publications Verification	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology Cancer
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .

HY-109166

Amdakefalin	Opioid Receptor	Neurological Disease
Amdakefalin is a μ and δ opioid receptors agonist with analgesic effects .

HY-P10200

CP7-FP13-2	Bacterial	Infection
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .

HY-P5161

FC382K10W15	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research .

HY-P5161A

FC382K10W15 TFA	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-P11279

TC2	GLP Receptor GCGR Neuropeptide Y Receptor	Metabolic Disease
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC₅₀ values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .

HY-P11759

Myr-transportan-Cys	Drug Derivative	Cancer
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .

HY-N17580

Lyciumin D	Renin	Cardiovascular Disease
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .

HY-P11604

C16 acid-I-{Lys(C10 diacid)}-KQELRRIGDEF	Phosphatase	Inflammation/Immunology
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC₅₀ values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .

HY-P11625

R9-13	RXFP Receptor	Cardiovascular Disease
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .

HY-P11586

San45	Amylin Receptor	Metabolic Disease
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14520

Tetrahydrofolic acid 5+ Cited Publications L-5,6,7,8-tetrahydrofolic acid; L-tetrahydrofolic acid	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Metabolic Disease Amino acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid .

HY-112169A

10-Formyltetrahydrofolic acid disodium	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
10-Formyltetrahydrofolic acid disodium is a form of tetrahydrofolic acid that acts as a donor of formyl groups in anabolism. 10-Formyltetrahydrofolic acid disodium can be used as a substrate for formyltransferase reactions and is involved in the biosynthesis of purines .

HY-112169

10-Formyltetrahydrofolic acid	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
10-Formyltetrahydrofolic acid is a form of tetrahydrofolic acid that acts as a donor of formyl groups in anabolism. 10-Formyltetrahydrofolic acid can be used as a substrate for formyltransferase reactions and is involved in the biosynthesis of purines .

HY-14520A

*(6S)-Tetrahydrofolic* acid** (6S)-5,6,7,8-tetrahydrofolic acid	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite
(6S)-Tetrahydrofolic acid is 1000-fold more active than the (6R) form at promoting the binding of fluorodeoxyuridylate to thymidylate synthase and 600-fold more active as a growth factor of P. cerevisiae. (6S)-Tetrahydrofolic acid also has a low affinity and high dissociation rate for folate-binding protein .

HY-N17580

Lyciumin D	Structural Classification Lycium barbarum L. Cyclopeptides Phenols Solanaceae Plants Source Classification	Renin
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .

Cat. No.	Product Name	Chemical Structure

HY-14520S

Tetrahydrofolic acid-d4

Tetrahydrofolic acid-d₄ is the deuterium labeled Tetrahydrofolic acid. Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-14520S1

Tetrahydrofolic acid-13C5

Tetrahydrofolic acid- ¹³C₅ (L-5,6,7,8-Tetrahydrofolic acid- ¹³C₅) is ¹³C labeled Tetrahydrofolic acid. Tetrahydrofolic acid (L-5,6,7,8-Tetrahydrofolic acid) is the biologically active vitamin B9 folate derivative. Tetrahydrofolic acid is a donor of one-carbon groups for amino acids, nucleic acids, and lipids. Tetrahydrofolic acid serves as an acceptor of free formaldehyde, producing 5,10-methylenetetrahydrofolate-Tetrahydrofolic acid .

HY-132384S

5-Methyltetrahydrofolic acid-d3
5-(Methyl-d₃)tetrahydrofolic Acid is the deuterium labeled 5-(Methyl)tetrahydrofolic Acid .

HY-P0014AS

Liraglutide-d8 tetraTFA
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

Cat. No.	Product Name		Classification

HY-W048490

*7-Deaza-2'-deoxy-7-iodoadenosine*		Nucleoside Analogs Adenosine
7-Deaza-2'-deoxy-7-iodoadenosine is an important deoxynucleoside that can be used in the synthesis of other active compounds .

HY-W048513

*7-Deaza-2'-deoxyadenosine*		Nucleoside Analogs Adenosine
7-Deaza-2'-deoxyadenosine is an isosteric dATP analog of 2'-deoxyadenosine. 7-Deaza-2'-deoxyadenosine is recognized by various DNA polymerases and incorporated into DNA strands as a substrate. 7-Deaza-2'-deoxyadenosine undergoes a bioorthogonal inverse electron demand Diels-Alder reaction with tetrazine-modified molecules, enabling site-specific labeling of DNA, surface antibody immobilization and intracellular fluorescent labeling. 7-Deaza-2'-deoxyadenosine reduces the DNA curvature of d(A₆)·d(T₆) fragments and the stability of DNA/RNA double helices, and leads to decreased antisense activity against SV40 T Antigen. 7-Deaza-2'-deoxyadenosine finds application in the research field of SV40 T Antigen-related cancers .

HY-132143B

*7-Deaza-7-propargylamino-dATP TEA*		Nucleotide Analogs Adenine Nucleotide
7-Deaza-7-propargylamino-dATP TEA is an analog of deoxyadenosine triphosphate (dATP) that can be used for gene sequencing .

HY-W048492

*7-Iodo-7-deaza-2'-deoxyguanosine* 7-deaza-7-Iodo-2'-deoxyguanosine		Nucleoside Analogs Guanosine
7-Iodo-7-deaza-2'-deoxyguanosine (7-Deaza-7-Iodo-2'-deoxyguanosine) is a modified deoxyguanosine nucleoside. 7-Iodo-7-deaza-2'-deoxyguanosine is used in DNA synthesis and sequencing reactions .

HY-138590

*7-TFA-ap-7-Deaza-dA*		Nucleoside Analogs Adenosine
7-TFA-ap-7-Deaza-dA is a modified nucleoside. 7-TFA-ap-7-Deaza-dA can be used in the synthesis of deoxyribonucleic acid or nucleic acid. 7-TFA-ap-7-Deaza-dA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W091788

*(2S,3R,5S)-7-Deaza-2'-deoxy-7-iodoadenosine*		Nucleoside Analogs Adenosine
(2S,3R,5S)-7-Deaza-2'-deoxy-7-iodoadenosine is the isomer of 7-Deaza-2'-deoxy-7-iodoadenosine (HY-W048490), and can be used as an experimental control. 7-Deaza-2'-deoxy-7-iodoadenosine is a modified oligonucleotide containing 7-Deazaadenine .

HY-152815

*2′-Deoxy-2′-fluoro-3-deaza-arabinouridine*		Nucleoside Analogs Uridine
2′-Deoxy-2′-fluoro-3-deaza-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-W048479

*7-Iodo-2',3'-dideoxy-7-deaza-guanosine* 1 Publications Verification		Nucleoside Analogs Guanosine
7-Iodo-2',3'-dideoxy-7-deaza-guanosine is a dideoxynucleoside that can be used in DNA synthesis and sequencing reactions .

HY-138591

*7-Deaza-2',3'-dideoxyadenosine*		Nucleoside Analogs Adenosine
7-Deaza-2',3'-dideoxyadenosine can be used in the synthesis of oligodeoxyribonucleotides .

HY-132140A

*7-Deaza-7-propargylamino-3'-azidomethyl-dGTP triethylamine*		Nucleotide Analogs
7-Deaza-7-propargylamino-3'-azidomethyl-dGTP triethylamine is an analog of deoxyguanosine triphosphate (dGTP) that widely used in the next generation sequencing (NGS) .

HY-152556

*3-Deaza-4’-C-methyluridine*		Nucleoside Analogs Uridine
3-Deaza-4’-C-methyluridine, 4-Hydroxy-1-β-D-(4-C-methylribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-154131

*3-Deaza-xylouridine*		Nucleoside Analogs Uridine
3-Deaza-xylouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152831

*2-Amino-8-aza-7-deaza-7-iodoguanosine*		Nucleoside Analogs Guanosine
2-Amino-8-aza-7-deaza-7-iodoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-152992

*7-Cyano-7-deaza-2'-deoxy guanosine*		Nucleoside Analogs Guanosine
7-Cyano-7-deaza-2'-deoxy guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7) .

HY-138589

*7-TFA-ap-7-Deaza-dG*		Nucleoside Analogs Guanosine
5'-O-TBDMS-dG is a modified nucleoside. 5'-O-DMT-2'-O-TBDMS-rI can be used in the synthesis of deoxyribonucleic acid or nucleic acid. 7-TFA-ap-7-Deaza-dG is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-134245

7-Deazaadenosine 5'-phosphate Tubercidin 5'-phosphate; 7-deaza-AMP		Nucleotide Analogs Adenine Nucleotide
7-Deazaadenosine 5'-phosphate (Tubercidin 5'-phosphate; 7-Deaza-AMP) is a potential substrate or competitive inhibitor of enzymes that interact with 5′-adenylic acid monophosphate. As a nucleotide derivative, 7-Deazaadenosine 5'-phosphate can regulate cellular functions by affecting intracellular signaling pathways, especially in signaling involving AMP .

HY-154316

*3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-3-Deaza-arabinouridine*		Nucleoside Analogs Uridine
3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-3-Deaza-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

HY-W048518

*7-Deaza-2'-dG* 7-deaza-2'-deoxyguanosine		Nucleoside Analogs Nucleotide Analogs
7-Deaza-2'-dG (7-Deaza-2'-deoxyguanosine) is a monomeric raw material that can be used for nucleic acid synthesis.

HY-178689

*7-Deaza-GTP*		Nucleoside Analogs Nucleotide Analogs
7-Deaza-GTP is a monomeric raw material that can be used for nucleic acid synthesis.

HY-182181

*7-Deaza-8-aza-dG-CE phosphoramidite (PPG)*		Phosphoramidites Guanine
7-Deaza-8-aza-dG-CE phosphoramidite (PPG) is a phosphoramidite that can be used in the synthesis of oligonucleotides.

HY-185219

*7-Deaza-dG-CE phosphoramidite*		Phosphoramidites Guanine
7-Deaza-dG-CE phosphoramidite is a phosphoramidite that can be used in the synthesis of oligonucleotides.

HY-132139A

*7-Deaza-7-propargylamino-3'-azidomethyl-dATP triethylamine*		Nucleotide Analogs
7-Deaza-7-propargylamino-3'-azidomethyl-dATP triethylamine is an analog of deoxy adenosine triphosphate (dATP) that widely used in the next generation sequencing (NGS) .

HY-W1121780

*7-Deaza-dA(Bz)-CE phosphoramidite*		Phosphoramidites Adenine
7-Deaza-dA(Bz)-CE phosphoramidite is a phosphoramidite that can be used in the synthesis of oligonucleotides.

HY-178632

*2'-O-Me-7-deaza-rA*		Nucleoside Analogs Nucleotide Analogs
2'-O-Me-7-deaza-rA is a monomeric raw material that can be used for nucleic acid synthesis.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

5-deaza-5,6,7,8-tetrahydrofolic acid

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products